These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 12734781

  • 1. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.
    Massi Benedetti M, Humburg E, Dressler A, Ziemen M.
    Horm Metab Res; 2003 Mar; 35(3):189-96. PubMed ID: 12734781
    [Abstract] [Full Text] [Related]

  • 2. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group.
    Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
    [Abstract] [Full Text] [Related]

  • 3. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC.
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [Abstract] [Full Text] [Related]

  • 4. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes.
    Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A, European Insulin Glargine Study Group.
    Diabetes Metab Res Rev; 2005 Jan; 21(6):545-53. PubMed ID: 16021649
    [Abstract] [Full Text] [Related]

  • 5. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
    Warren E, Weatherley-Jones E, Chilcott J, Beverley C.
    Health Technol Assess; 2004 Nov; 8(45):iii, 1-57. PubMed ID: 15525480
    [Abstract] [Full Text] [Related]

  • 6. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.
    Pan CY, Sinnassamy P, Chung KD, Kim KW, LEAD Study Investigators Group.
    Diabetes Res Clin Pract; 2007 Apr; 76(1):111-8. PubMed ID: 17011662
    [Abstract] [Full Text] [Related]

  • 7. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A, Schweitzer MA, Häring HU, 4001 Study Group.
    Ann Intern Med; 2003 Jun 17; 138(12):952-9. PubMed ID: 12809451
    [Abstract] [Full Text] [Related]

  • 8. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR, Gilbert RE, Yue DK.
    Intern Med J; 2005 Sep 17; 35(9):536-42. PubMed ID: 16105155
    [Abstract] [Full Text] [Related]

  • 9. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
    Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators.
    Diabetes Care; 2003 Nov 17; 26(11):3080-6. PubMed ID: 14578243
    [Abstract] [Full Text] [Related]

  • 10. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
    Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C.
    Nutr Metab Cardiovasc Dis; 2009 Oct 17; 19(8):571-9. PubMed ID: 18676131
    [Abstract] [Full Text] [Related]

  • 11. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
    Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, Johnston P, Davis M.
    Diabetologia; 2009 Sep 17; 52(9):1778-88. PubMed ID: 19526210
    [Abstract] [Full Text] [Related]

  • 12. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
    Rosenstock J, Schwartz SL, Clark CM, Park GD, Donley DW, Edwards MB.
    Diabetes Care; 2001 Apr 17; 24(4):631-6. PubMed ID: 11315821
    [Abstract] [Full Text] [Related]

  • 13. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2021 Mar 04; 3(3):CD013498. PubMed ID: 33662147
    [Abstract] [Full Text] [Related]

  • 14. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.
    Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA.
    Diabetes Care; 2000 May 04; 23(5):639-43. PubMed ID: 10834423
    [Abstract] [Full Text] [Related]

  • 15. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.
    Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P.
    Cardiovasc Diabetol; 2009 Jan 19; 8():3. PubMed ID: 19152692
    [Abstract] [Full Text] [Related]

  • 16. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.
    Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K, Tulokas T, Hulme S, Hardy K, McNulty S, Hänninen J, Levänen H, Lahdenperä S, Lehtonen R, Ryysy L.
    Diabetologia; 2006 Mar 19; 49(3):442-51. PubMed ID: 16456680
    [Abstract] [Full Text] [Related]

  • 17. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin.
    Siegmund T, Weber S, Blankenfeld H, Oeffner A, Schumm-Draeger PM.
    Exp Clin Endocrinol Diabetes; 2007 Jun 19; 115(6):349-53. PubMed ID: 17701878
    [Abstract] [Full Text] [Related]

  • 18. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
    Owens DR, Traylor L, Mullins P, Landgraf W.
    Diabetes Res Clin Pract; 2017 Feb 19; 124():57-65. PubMed ID: 28092788
    [Abstract] [Full Text] [Related]

  • 19. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J, Cohen N, Evans M, Hockey A, Speight J, Whately-Smith C.
    Diabetes Obes Metab; 2015 Dec 19; 17(12):1133-41. PubMed ID: 26085028
    [Abstract] [Full Text] [Related]

  • 20. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.
    Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB.
    Diabet Med; 2004 Nov 19; 21(11):1213-20. PubMed ID: 15498088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.